XML 51 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1

Material Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Supplemental Agreement [Abstract]
Revenues		$ 13,267	$ 27,146	$ 50,606	$ 54,723
License and Royalty Revenue [Member]
Supplemental Agreement [Abstract]
Revenues		3,355	$ 17,351	$ 17,387	22,820
Commercial Exploitation Agreement with Indivior [Member]
Commercial Exploitation Agreement [Abstract]
License agreement term				7 years
Automatic renewal period of agreement				1 year
Commercial Exploitation Agreement with Indivior [Member] | Minimum [Member]
Commercial Exploitation Agreement [Abstract]
Notice period of intent not to renew agreement				1 year
Supplemental Agreement with Indivior [Member]
Supplemental Agreement [Abstract]
Receivable, Issuance of process patent rights		2,500		$ 2,500
Supplemental Agreement with Indivior [Member] | Maximum [Member]
Supplemental Agreement [Abstract]
Receivable, Additional amounts		41,500		41,500
Receivable, Milestone payments and royalties		39,000		39,000
Receivable, Issuance of process patent rights		75,000		75,000
Supplemental Agreement with Indivior [Member] | License and Royalty Revenue [Member]
Supplemental Agreement [Abstract]
Revenues	$ 17,000	3,000		16,500
License Agreement with Sunovion Pharmaceuticals, Inc. [Member]
License Agreement [Abstract]
Revenues, Milestone revenues recognized				0	5,000
License Agreement with Sunovion Pharmaceuticals, Inc. [Member] | Maximum [Member]
License Agreement [Abstract]
Remaining milestone payments, Regulatory events		11,000		11,000
Remaining milestone payments, Commercial events		$ 20,000		20,000
Collaboration and License Agreement with Mitsubishi Tanabe [Member]
Supplemental Agreement [Abstract]
Revenues				240
Agreement to Terminate CLA with KemPharm [Member]
Supplemental Agreement [Abstract]
Revenues				$ 0	$ 0

X

- Definition

Potential additional payments receivable under the agreement, relating to issuance of additional process patent rights as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	aqst_AdditionalPaymentReceivableFromIssuanceOfProcessPatentRights
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Period for which the agreement is renewed automatically.

+ References

No definition available.

+ Details

Name:	aqst_AutomaticRenewalPeriodOfAgreement
Namespace Prefix:	aqst_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	aqst_CommercialExploitationAgreementAbstract
Namespace Prefix:	aqst_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	aqst_LicenseAgreementAbstract
Namespace Prefix:	aqst_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

License agreement term period.

+ References

No definition available.

+ Details

Name:	aqst_LicenseAgreementTerm
Namespace Prefix:	aqst_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Notice period of intent not to renew agreement, prior to the expiration of the initial or renewal term.

+ References

No definition available.

+ Details

Name:	aqst_NoticePeriodForNotToRenewAgreement
Namespace Prefix:	aqst_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Potential additional payment receivable under the agreement as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	aqst_ReceivableAdditionalAmounts
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Potential additional payments receivable under the agreement, relating to milestones and royalties as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	aqst_ReceivableMilestonePaymentsAndRoyalties
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Commercial milestone events receivable, that are contingent on the achievement of certain sales levels.

+ References

No definition available.

+ Details

Name:	aqst_RemainingMilestonePaymentCommercialEvents
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Remaining milestone payment received for regulatory events as of the balance sheet date.

+ References

No definition available.

+ Details

Name:	aqst_RemainingMilestonePaymentRegulatoryEvents
Namespace Prefix:	aqst_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- References

No definition available.

+ Details

Name:	aqst_SupplementalAgreementAbstract
Namespace Prefix:	aqst_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

No definition available.

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=aqst_LicenseAndRoyaltyRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=aqst_CommercialExploitationAgreementWithIndiviorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=aqst_SupplementalAgreementWithIndiviorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=aqst_LicenseAgreementWithSunovionPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=aqst_CollaborationAndLicenseAgreementWithMitsubishiTanabeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=aqst_AgreementToTerminateCLAWithKemPharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: